OrthoSensor says it pulled in a $17 million funding round for its Verasense knee implant technology.
OrthoSensor said it pulled in a funding round worth nearly $17 million that it hopes will eventually add up to $19 million.
The Florida maker of knee implant placement technology disclosed the round in a recent regulatory filing.
Stryker Corp. says it plans to buy back up to $2 billion worth of its own stock.
Stryker (NYSE:SYK) said today that its board of directors authorized a share repurchasing program worth up to $2 billion.
A federal appeals court overturns the lost profits awarded to Medtronic in its long-running patent infringement war with NuVasive.
Here's a look at some of the top regulatory stories for medical device companies this week: FDA clears new version of Boston Scientific's SpyGlass; Joint FDA panel recommends OK for Avedro's eye treatment; Staar Surgical posts Q4, 2014 losses; FDA removes unregistered medical device establishments from database; FDA panel to review brain aneurysm devices
AngioDynamics inks a deal to invest in EmboMedics and its ResoSphere resorbable embolic microsphere technology, with a possible acquisition on the table.
Siemens says it's investigating a Chinese media report that its healthcare business inflated its numbers by citing faked contracts.
(Reuters) — Germany's Siemens said it's investigating a media report that it boosted sales figures of its healthcare equipment in China by creating fake contracts.
A pivotal trial of Tryton Medical's side-branch stent fails to meet its non-inferiority endpoint for target vessel failure, although most of the patients in the study fell outside its target parameters.
A pivotal clinical trial of Tryton Medical's side-branch stent, the largest ever conducted on coronary bifurcation lesions, failed to meet its primary endpoint for target vessel failure.
